

INSTITUTIONAL BIOSAFETY COMMITTEE MEETING
October 18, 2017
3 PM, Plant Biotechnology Building, Room 410

MEMBERS PRESENT: Chair, David White; Vice Chair, Elizabeth Fozo; Tamara Chavez-Lindell, Lori Cole, Doris D'Souza, Paul Dalhaimer, George Dizikes, Brittany Isabell, Jun Lin, Reginald Millwood, Deidra Mountain

Ex-Officio –Brian Ranger, Jessica Woofter

MEMBERS ABSENT: Marc Caldwell, Reza Hajimorad, Melissa Kennedy, Jae Park, Ling Zhao

OTHERS PRESENT:

Opening:

The meeting was called to order by the Chair, Dr. David White at 3:03 PM. The minutes of September 22, 2017, were reviewed and approved as written.

IBC Applications:

#IBC-17-503-1 (Datta Subimal) Acute Biological Toxin, New registration

Dr. Datta's research covers molecular and physiological mechanisms of stress-induced sleep disorders. Specifically, he will be using tetrodotoxin (TTX) in an animal model (rat) to create temporary lesions in targeted regions of the brain. Briefly, 1 mg of the toxin will be suspended in 20 ml of buffer. 200 nl (10 ng) of the toxin solution will be applied through intracranial cannula to the target site in accordance with an approved animal protocol. Toxin preparation/dilution will be performed in a primary containment device. All remaining stock will be immediately inactivated by bleach (1:10; final vol:vol). No toxin will be retained or stored after each procedure (i.e. maximum quantity in possession is only 1 mg). The committee voted to approve Dr. Subimal Datta's registration pending IACUC approval and protocol specific training.

Old Business:

Administrative Report

i. Contingencies

Following up on September 22, 2017, IBC meeting, Dr. Cong Trinh's registration (#17-450-2) was edited by the Principal Investigator to remove the needle recapping procedures from the registration.

ii. Administrative Approvals

Dr. Jay Whelan's registration (#14-425-2) was administratively approved to include the use of human cell lines (prostate cells, normal and carcinomas) for use in various *in vitro* and *in vivo* (xenograft) experiments.

iii. Administrative Terminations

None.

iv. Administrative Exemptions:

None.

- v. *Accidents, Injuries/Exposures:*
None.
- vi. *Laboratory Report (Hamilton)*
None.
- vii. *iMedRIS Update, Manual Reviews, & System Orientation (Woofter)*
None.

Charter Revision Update

Dr. Liz Fozo indicated that the charter subcommittee would be meeting the following week to review the first set of revisions to the charter.

Zika Trial Update

Brian Ranger gave an update on the zika project and provided pictures of the layout of the trial location. Additionally, a town hall meeting was held for all the occupants of the building to provide transparency about the project and to review the security and safety measures that have been implemented.

Proposed undergraduate project involving high-risk human blood samples

Brian notified the committee of a request for clinical samples from the regional health department. Because these samples are likely to contain bloodborne or other adventitious agents, the committee agreed that the risk was likely too high for an undergraduate project. Additional discussion was tabled pending further discussion with the principal investigator.

2017 Refresher Training

Brian notified the committee that everyone listed in diagnostic labs, USDA permits, and IBC registrations will be required to complete refresher training regardless of biological safety level.

Peer Review with Clemson University

Marsha Smith and Brian Ranger will be going to Clemson next week for peer review of Clemson's compliance/safety program management.

New Business:

Biosafety Newsletter

Brian notified the committee that our office is working on a quarterly newsletter to provide updates, and asked the committee for suggestions on names or items to add to the newsletter.

The meeting adjourned at 3:55 pm. The next meeting has been tentatively scheduled for November 15, 2017, in the Plant Biotechnology Building, Room 410.